1.Endoscopic third ventriculostomy in treatment of pediatric obstructive hydrocephalus
Guan SUN ; Jun GUO ; Dekang NIE ; Nan JIANG ; Linshan FU
Chinese Journal of Neuromedicine 2016;15(9):941-944
Objective To analyze the surgical technique and success rate of endoscopic third ventriculostomy (ETV) in pediatric obstructive hydrocephalus.Methods A retrospective analysis of clinical data and treatment efficacy of 13 patients with pediatric obstructive hydrocephalus,admitted to and undergone ETV in our hospital fiom July 2008 to July 2014,was performed.All patients were confirmed by CT and MR imaging.Results Follow-up information for all patients was obtained every 6 months by telephone after operation.Re-check was performed in all patients by CT or MR imaging.Ten had signs of hydrocephalus greatly relieved or disappeared;3 were invalid,and ventriculoperitoneal shunt was then performed 3-12 months after ETV.Postoperative fever occurred in 2 children and epilepsy in one.No complications,such as cerebrospinal fluid leakage,bleeding,infection or nerve injury,were noted.Conclusion ETV in treatment of children with obstructive hydrocephalus is safe and effective,enjoying few complications.
2.Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice.
Lili DING ; Qiaoling YANG ; Eryun ZHANG ; Yangmeng WANG ; Siming SUN ; Yingbo YANG ; Tong TIAN ; Zhengcai JU ; Linshan JIANG ; Xunjiang WANG ; Zhengtao WANG ; Wendong HUANG ; Li YANG
Acta Pharmaceutica Sinica B 2021;11(6):1541-1554
Obesity and its associated complications are highly related to a current public health crisis around the world. A growing body of evidence has indicated that G-protein coupled bile acid (BA) receptor TGR5 (also known as Gpbar-1) is a potential drug target to treat obesity and associated metabolic disorders. We have identified notoginsenoside Ft1 (Ft1) from